Autologous stem cell transplantation for systemic sclerosis

References

• Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23(5):581–590.
   Google Scholar
• Medsger TA, Jr., Masi AT. Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med 1971; 74(5)714–721
   PubMed Web of Science ®Google Scholar
• Mayes MD, Lacey JV, Jr., Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48(8)2246–2255
   PubMedGoogle Scholar
• Arnett FC, Cho M, Chatterjee S, et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001; 44(6)1359–1362
   PubMedGoogle Scholar
• Czirjak L, Kiss CG, Lovei C, et al. Survey of Raynaud's phenomenon and systemic sclerosis based on a representative study of 10,000 south-Transdanubian Hungarian inhabitants. Clin Exp Rheumatol 2005; 23(6)801–808
   PubMedGoogle Scholar
• Furst DE, Clements PJ. Hypothesis for the pathogenesis of systemic sclerosis. J Rheumatol Suppl 1997; 48: 53–57
   PubMedGoogle Scholar
• Lambert NC, Erickson TD, Yan Z, et al. Quantification of maternal microchimerism by HLA-specific real-time polymerase chain reaction: Studies of healthy women and women with scleroderma. Arthritis Rheum 2004; 50(3)906–914
   PubMedGoogle Scholar
• Abraham DJ, Varga J. Scleroderma: From cell and molecular mechanisms to disease models. Trends Immunol 2005; 26(11)587–595
   PubMed Web of Science ®Google Scholar
• Denton CP, Black CM. Targeted therapy comes of age in scleroderma. Trends Immunol 2005; 26(11)596–602
   PubMedGoogle Scholar
• Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: Demographic, clinical, and serologic features and survival in 1012 Italian patients. Medicine (Baltimore) 2002; 81(2)139–153
   PubMed Web of Science ®Google Scholar
• Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81(2)154–167
   PubMed Web of Science ®Google Scholar
• Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66(6)754–763
   PubMed Web of Science ®Google Scholar
• Mayes MD. Race, scleroderma, and survival: Why is there a difference?. J Rheumatol 2005; 32(10)1873–1874
   PubMed Web of Science ®Google Scholar
• Bulpitt KJ, Clements PJ, Lachenbruch PA, et al. Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993; 118(8)602–609
   PubMedGoogle Scholar
• Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: Development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42(12)2660–2665
   PubMedGoogle Scholar
• Kuwana M, Kaburaki J, Okano Y, et al. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37(1)75–83
   PubMedGoogle Scholar
• Steen VD, Powell DL, Medsger TA, Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31(2)196–203
   PubMedGoogle Scholar
• Kuwana M, Kaburaki J, Mimori T, et al. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000; 43(5)1074–1084
   PubMedGoogle Scholar
• Steen VD, Medsger TA, Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43(11)2437–2444
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: An international meta-analysis of individual patient data. Am J Med 2005; 118(1)2–10
   PubMed Web of Science ®Google Scholar
• Farge D, Henegar C, Carmagnat M, et al. Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. Arthritis Rheum 2005; 52(5)1555–1563
   PubMedGoogle Scholar
• Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44(6)1351–1358
   PubMed Web of Science ®Google Scholar
• van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35(4)364–372
   PubMedGoogle Scholar
• Griffiths B, Miles S, Moss H, et al. Systemic sclerosis and interstitial lung disease: A pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002; 29(11)2371–2378
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354(25)2655–2666
   PubMed Web of Science ®Google Scholar
• Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54(12)3962–3970
   PubMed Web of Science ®Google Scholar
• Marmont A, Tyndall A, Gratwohl A, Vischer T. Hematopoietic precursor-cell transplants for autoimmune-diseases. Lancet 1995; 345: 978
   PubMed Web of Science ®Google Scholar
• Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: A consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19(7)643–645
   PubMed Web of Science ®Google Scholar
• Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: Procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60(6)577–584
   PubMed Web of Science ®Google Scholar
• McSweeney PA, Nash RA, Sullivan KM, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: Initial outcomes. Blood 2002; 100(5)1602–1610
   PubMed Web of Science ®Google Scholar
• Farge D, Marolleau JP, Zohar S, et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: Early results from a French multicentre phase I–II study. Br J Haematol 2002; 119(3)726–739
   PubMedGoogle Scholar
• Saccardi R, Tyndall A, Coghlan G, et al. Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant 2004; 34(10)877–881
   PubMedGoogle Scholar
• Farge D, Passweg J, van Laar JM, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: Report from the EBMT/EULAR Registry. Ann Rheum Dis 2004; 63(8)974–981
   PubMed Web of Science ®Google Scholar
• Vonk MC, Marjanovic Z, van den Hoogen FH, et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 2008; 67(1)98–104
   PubMed Web of Science ®Google Scholar
• van Bekkum DW. Effectiveness and risks of total body irradiation for conditioning in the treatment of autoimmune disease with autologous bone marrow transplantation. Rheumatology (Oxford) 1999; 38(8)757–761
   PubMedGoogle Scholar
• van Bekkum DW. Conditioning regimens for the treatment of experimental arthritis with autologous bone marrow transplantation. Bone Marrow Transplant 2000; 25(4)357–364
   PubMed Web of Science ®Google Scholar
• Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: Long-term follow-up of the US multicenter pilot study. Blood 2007; 110(4)1388–1396
   PubMed Web of Science ®Google Scholar
• Verrecchia F, Laboureau J, Verola O, et al. Skin involvement in scleroderma—where histological and clinical scores meet. Rheumatology (Oxford) 2007; 46(5)833–841
   PubMedGoogle Scholar
• Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998; 92(5)1471–1490
   PubMed Web of Science ®Google Scholar
• Talvensaari K, Clave E, Douay C, et al. A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantation. Blood 2002; 99(4)1458–1464
   PubMedGoogle Scholar
• Douek DC, Vescio RA, Betts MR, et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 2000; 355(9218)1875–1881
   PubMed Web of Science ®Google Scholar
• Yurovsky VV. The repertoire of T-cell receptors in systemic sclerosis. Crit Rev Immunol 1995; 15(2)155–165
   PubMedGoogle Scholar
• Sakkas LI, Platsoucas CD. Is systemic sclerosis an antigen-driven T cell disease?. Arthritis Rheum 2004; 50(6)1721–1733
   PubMedGoogle Scholar
• Gratwohl A, Passweg J, Bocelli-Tyndall C, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant 2005; 35(9)869–879
   PubMed Web of Science ®Google Scholar
• Kapoor S, Wilson AG, Sharrack B, et al. Haemopoietic stem cell transplantation—an evolving treatment for severe autoimmune and inflammatory diseases in rheumatology, neurology and gastroenterology. Hematology 2007; 12(3)179–191
   PubMed Web of Science ®Google Scholar
• van Laar JM, Farge D, Tyndall A. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: Hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis 2005; 64(10)1515
   PubMedGoogle Scholar
• Nash RA, Dansey R, Storek J, et al. Epstein–Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant 2003; 9(9)583–591
   PubMedGoogle Scholar
• Nash RA, McSweeney PA, Nelson JL, et al. Allogeneic marrow transplantation in patients with severe systemic sclerosis: Resolution of dermal fibrosis. Arthritis Rheum 2006; 54(6)1982–1986
   PubMedGoogle Scholar
• Loh Y, Oyama Y, Statkute L, et al. Non-myeloablative allogeneic hematopoietic stem cell transplantation for severe systemic sclerosis: Graft-versus-autoimmunity without graft-versus-host disease?. Bone Marrow Transplant 2007; 39(7)435–437
   PubMed Web of Science ®Google Scholar